Európska únia - angličtina - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - irbesartan, hydrochlorothiazide - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension.this fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone (see section 5.1).

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - daclatasvir dihydrochloride 33mg equivalent to daclatasvir 30mg - tablet - 30 mg - active: daclatasvir dihydrochloride 33mg equivalent to daclatasvir 30mg excipient: colloidal silicon dioxide croscarmellose sodium lactose magnesium stearate microcrystalline cellulose opadry green - daklinza is indicated in combination with other medicinal products for the treatment of chronic hepatitis c virus (hcv) infection in adults with compensated liver disease (including cirrhosis).

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - daclatasvir dihydrochloride 66mg equivalent to daclatasvir 60mg - tablet - 60 mg - active: daclatasvir dihydrochloride 66mg equivalent to daclatasvir 60mg excipient: colloidal silicon dioxide croscarmellose sodium lactose magnesium stearate microcrystalline cellulose opadry green - daklinza is indicated in combination with other medicinal products for the treatment of chronic hepatitis c virus (hcv) infection in adults with compensated liver disease (including cirrhosis).

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - asunaprevir -

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - abatacept 262.5mg;  ;   - powder for injection - 250 mg - active: abatacept 262.5mg     excipient: hydrochloric acid maltose monobasic sodium phosphate dihydrate sodium chloride sodium hydroxide - orencia in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have had an insufficient response or intolerance to other disease modifying anti-rheumatic drugs (dmards), such as methotrexate or tumour necrosis factor (tnf) blocking agents. a reduction in the progression of joint damage and improvement in physical function have been demonstrated during combination treatment with orencia and methotrexate. orencia in combination with methotrexate is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. orencia is indicated for reducing signs and symptoms in paediatric patients 6 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). orencia may be used concomitantly with methotrexate (mtx). (there is no clinical trial data for the use of orencia subcutaneous formulation in children, therefore its use in children cannot be recommended.) orencia should not be administered concurrently with other biological dmards (eg, tnf inhibitors, rituximab, or anakinra).

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - abatacept 125.875mg equivalent to abatacept 125mg/ml;  ;   - solution for injection - 125 mg - active: abatacept 125.875mg equivalent to abatacept 125mg/ml     excipient: dibasic sodium phosphate monobasic sodium phosphate nitrogen poloxamer 188 sucrose water for injection - orencia in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have had an insufficient response or intolerance to other disease modifying anti-rheumatic drugs (dmards), such as methotrexate or tumour necrosis factor (tnf) blocking agents. a reduction in the progress of joint damage and improvement in physical function have been demonstrated during combination treatment with orencia and methotrexate. orencia in combination with methotrexate is also indicated in the treatment of severe, active and progressive rheumatoid arthiritis in adults not previously treated with methotrexate. orencia should not be administered concurrently with other dmards (eg. tnf inhibitors, rituximab or anakinra).

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - paclitaxel 6 mg/ml - concentrate for infusion - 6 mg/ml - active: paclitaxel 6 mg/ml excipient: ethanol polyoxyl 35 castor oil

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

bristol-myers squibb (holdings) limited - amikacin sulfate - solution for injection - 100 mg/2ml - other aminoglycosides

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - triamcinolone acetonide - suspension for injection - 10mg/1ml

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - triamcinolone acetonide - suspension for injection - 40mg/1ml